A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma)
Neoplasms, Head and Neck
DRUG: Dostarlimab|DRUG: Placebo
Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR), Event Free Survival (EFS) is defined as the time from the date of randomization to the date of an event, where an event is defined as locoregional progression or recurrence, or distant metastasis per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as per BICR; Salvage surgery at the primary tumor site; Neck dissection or surgery performed \>20 weeks after completion of or Death from any cause., Up to approximately 5 years
Overall Survival (OS), OS is defined as the time from date of randomization to the date of death by any cause., Up to approximately 5 years|Event-free Survival (EFS) assessed by investigator, Event Free Survival (EFS) is defined as the time from the date of randomization to the date of an event as per primary endpoint, however with investigator assessment per RECIST 1.1, Up to approximately 5 years|Number of Participants with treatment emergent adverse events (TEAEs), Immune-mediated TEAEs, and serious adverse events (SAEs) by severity, Up to approximately 5 years|Number of Participants with TEAEs and SAEs leading to dose delays, withdrawals or death, Up to approximately 5 years|Number of participants with clinically significant changes in laboratory, vital signs, and safety assessment parameters, Up to approximately 5 years|Serum Concentration of Dostarlimab, Up to approximately 15 months|Serum Concentration of Dostarlimab at End of Infusion (C-EoI), Up to approximately 15 months|Serum Predose trough concentration (Ctrough) of Dostarlimab, Up to approximately 15 months|Number of Participants with Anti-Drug Antibodies against Dostarlimab, Up to approximately 15 months
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma)